Parametric Portfolio Associates’s Spero Therapeutics SPRO Stock Holding History

Parametric Portfolio Associates’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$384K	Buy	+44,168	New	+$453K	﹤0.01%	3199
2021 Q4	–	Sell	-11,308	Closed	-$208K	–	3697
2021 Q3	$208K	Sell	11,308 -18,639	-62%	-$299K	﹤0.01%	3425
2021 Q2	$418K	Sell	29,947 -1,490	-5%	-$20.8K	﹤0.01%	3157
2021 Q1	$463K	Buy	31,437 +5,982	+24%	+$105K	﹤0.01%	3533
2020 Q4	$494K	Buy	+25,455	New	+$397K	﹤0.01%	3390
2020 Q3	–	Sell	-11,575	Closed	-$157K	–	3971
2020 Q2	$157K	Buy	+11,575	New	+$130K	﹤0.01%	3693
2020 Q1	–	Sell	-10,053	Closed	-$97K	–	4004
2019 Q4	$97K	Buy	+10,053	New	+$108K	﹤0.01%	3866

Other funds holding SPRO

Aquilo Capital Management San Francisco, California $37.1M AUM 41.76% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return